The start of a phase-1 trial for AB-343, a SARS-CoV-2 protease inhibitor, has been delayed. Previously, ABUS said phase-1 would start in 3Q23; now, ABUS says IND-enabling studies will be completed in 2H23 (which generally means 4Q23), which probably means the phase-1 start is slated for early 2024.